Backed by Eli Casdin, a DNA synthesis company gets a big Series C ahead of its first product launch
An Eli Casdin-backed company looking to shake up the business of DNA printing clinched a nine-figure raise to get its first product off the ground.
DNA Script closed its $165 million Series C on Tuesday morning, the company announced, giving it a new cash reservoir as it prepares the first product launch in the second half of next year. It’s a move that comes about 15 months after its last fundraise, when DNA Script netted a $50 million Series B in July 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.